Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Completed
Arena Pharmaceuticals
Phase 2
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which
included a dose titration period. An additional transition period occurred for those patients
who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients
with PAH were enrolled.
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Completed
United Therapeutics
Phase 2
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which
included a dose titration period. An additional transition period occurred for those patients
who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients
with PAH were enrolled.
Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
Completed
Arena Pharmaceuticals
Phase 2
This study is an open-label extension study to determine the long-term safety and
tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study,
APD811-003. Patients must have completed the APD811-003 study and must meet eligibility
criteria for APD811-007.
Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
Completed
United Therapeutics
Phase 2
This study is an open-label extension study to determine the long-term safety and
tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study,
APD811-003. Patients must have completed the APD811-003 study and must meet eligibility
criteria for APD811-007.
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Arena Pharmaceuticals
Phase 3
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
